TP Therapeutics has partnered with Almac Diagnostic Services for the development and commercialisation of next-generation sequencing (NGS) companion diagnostic (CDx) for the former’s oral small molecule drug, repotrectinib.
Almac will utilise ArcherDx’s Anchored Multiplex PCR (AMP) for the development of the CDx, which is to be submitted to the US FDA for regulatory approval.
The NGS diagnostic will be initially utilised at Almac laboratory in North Carolina to identify patients with targeted gene fusion tumours for repotrectinib treatment.
TP Therapeutics is a US-based developer of cancer therapeutics, while Almac is a medicine company and UK-based subsidiary of the Almac Group.
ViewRay has signed an agreement with GenesisCare to bring the first MRIdian MRI-guided radiotherapy system for cancer treatment to the UK.
A number of MRIdian linear accelerators will be installed across GenesisCare network under the agreement, with the first two systems planned to be installed in the UK.
The collaboration will help GenesisCare to accomplish its precision radiotherapy vision of providing improved and adaptive radiation medicine.
ViewRay is an American designer, manufacturer and marketer of the MRIdian® radiation therapy system, while GenesisCare is a UK-based oncology and cardiology services provider.
TSO3 has received a contract to supply its FDA-cleared STERIZONE® VP4 Sterilizers under a request for proposal issued by the Quebec Province.
STERIZONE is a low-temperature sterilisation system used for sterilisation of medical devices, which are sensitive to heat and moisture.
The CHU de Québec-Université Laval will purchase one STERIZONE® VP4 Sterilizer and have an option to purchase two additional sterilisers, under the contract.
Based in the US, TSO3 is a medical device company, while CHU de Québec – Université Laval is a Canadian network of hospitals affiliated to the Université Laval.
Germany-based medical device company Protembis has raised $10m in a Series A funding round.
A consortium of medical technology companies, including Abiomed, Seed Fonds III, Mönchengladbach and Coparion, as well as other angel investors, participated in the funding round.
The proceeds will be utilised to develop a new cerebral protection system designed to minimise the risk of stroke or other neurological injury.